Comparative Pharmacology
Head-to-head clinical analysis: ALBENZA versus EMVERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENZA versus EMVERM.
ALBENZA vs EMVERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
None Documented
None Documented
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Category C
Category C
Anthelmintic
Anthelmintic